Ryan M. Bartolucci Sells 339 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CAO Ryan M. Bartolucci sold 339 shares of the firm's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $40.23, for a total transaction of $13,637.97. Following the completion of the transaction, the chief accounting officer now directly owns 71,007 shares in the company, valued at $2,856,611.61. This represents a 0.48 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tempus AI Stock Performance

Shares of TEM stock traded down $4.66 during mid-day trading on Wednesday, hitting $34.29. 7,396,915 shares of the stock traded hands, compared to its average volume of 1,521,735. Tempus AI, Inc. has a 52-week low of $22.89 and a 52-week high of $79.49. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The stock's fifty day moving average price is $52.24.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on TEM. Bank of America lifted their price target on shares of Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a research note on Friday, December 13th. Wolfe Research initiated coverage on Tempus AI in a report on Friday, December 13th. They set an "outperform" rating and a $60.00 price objective on the stock. Loop Capital upped their target price on Tempus AI from $48.00 to $57.00 and gave the stock a "buy" rating in a report on Tuesday, October 15th. Guggenheim assumed coverage on Tempus AI in a research report on Monday, December 9th. They set a "buy" rating and a $74.00 price target on the stock. Finally, Stifel Nicolaus downgraded Tempus AI from a "buy" rating to a "hold" rating and lifted their price objective for the company from $45.00 to $65.00 in a report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Tempus AI has an average rating of "Moderate Buy" and a consensus price target of $56.00.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. boosted its holdings in Tempus AI by 1.0% in the third quarter. Franklin Resources Inc. now owns 811,311 shares of the company's stock worth $45,920,000 after acquiring an additional 8,387 shares in the last quarter. Tidal Investments LLC purchased a new position in shares of Tempus AI in the 3rd quarter valued at approximately $7,633,000. Teachers Retirement System of The State of Kentucky boosted its stake in Tempus AI by 6.3% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 126,500 shares of the company's stock worth $7,160,000 after purchasing an additional 7,500 shares in the last quarter. Geode Capital Management LLC grew its position in Tempus AI by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company's stock worth $7,537,000 after purchasing an additional 539 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Tempus AI during the 3rd quarter valued at approximately $502,000. Hedge funds and other institutional investors own 24.22% of the company's stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.